Republicans Push Back Against Rx Pricing Transparency Bills At House Hearing
Executive Summary
Pricing transparency legislation requests too much information, Republicans say during hearing in US House Energy and Commerce Subcommittee on Health.
You may also be interested in...
Senate Drug Pricing Legislation Clears Committee With Generic Exclusivity “Parking” Provision Unchanged
US Senate health committee advanced the Lower Health Care Costs Act with few pharma-related changes. Bill’s drug pricing provisions include the CREATES Act and a requirement that manufacturers report to HHS on price increases.
Drug Pricing And The AOC Effect
Alexandria Ocasio-Cortez’ social media celebrity gives the first-year Democratic member of Congress an outsize influence – and she is making pharmaceutical industry profits a priority target. But she is also having a unifying effect in rallying Republicans behind industry.
House Judiciary Committee Advances Four Drug Pricing Bills, Although Changes Are Still Likely
US committee will likely re-examine the language regarding the burden of proof in a bill prohibiting pay-for-delay settlements.